University of Cagliari
Modelling chemotherapy-induced cardiotoxicity by human pluripotent stem cells
CADEDDU DESSALVI, CHRISTIAN;DEIDDA, MARTINO;MERCURO, GIUSEPPE
2017-01-01
Abstract
Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing to new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy . In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| Madonna Current Drug Targets, 2016,.pdf Solo gestori archivio
Type: versione editoriale
Size 211.28 kB
Format Adobe PDF
|
211.28 kB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.